Challenges in designing and executing clinical trials in a dish studies

Area of Science:

• Biomedical Engineering
• Stem Cell Biology
• Pharmacology

Background:

• Rising drug discovery costs necessitate improved preclinical to clinical trial bridging strategies.
• Human induced pluripotent stem cells (iPSCs) differentiate into cell types that recapitulate patient-specific drug responses.
• Clinical Trials in a Dish (CTiD) offers an in vitro platform for pre-clinical drug safety and efficacy testing.

Purpose of the Study:

• To outline critical considerations for designing and implementing robust Clinical Trials in a Dish (CTiD) studies.
• To ensure the scientific integrity and reliability of stem cell-based in vitro drug testing.
• To establish quality metrics for CTiD platforms to enhance reproducibility.

Main Methods:

• Discussion of key elements for CTiD study design, implementation, and execution.
• Emphasis on quality metrics from tissue acquisition to data generation.
• Assessment of processes to ensure CTiD reliably mimics clinical trials.

Main Results:

• CTiD leverages patient-specific iPSC-derived cells to predict in vivo drug responses.
• Standardized processes and quality metrics are currently lacking for stem cell-based in vitro testing.
• Careful design is crucial for the scientific integrity of CTiD constructs.

Conclusions:

• CTiD holds promise for reducing drug development costs and improving decision-making.
• Implementing rigorous quality standards is paramount for the validity of CTiD studies.
• Standardized CTiD approaches will yield reproducible and reliable experimental data for drug development.